Press release
Vaccine Adjuvants Market worth $0.96 billion by 2029
The market for vaccine adjuvants market is competitive, with key players strategizing to capture the majority market share. Prominent players in the vaccine adjuvants market are GSK Plc (UK), SEPPIC (France)
The global vaccine adjuvants market [https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr], valued at US$0.66 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$0.70 billion in 2024 and an impressive US$0.96 billion by 2029. The rise in global vaccination programs, rising demand for effective vaccines against emerging infectious diseases, and growing investments in vaccine and vaccine adjuvant research are some of the major factors propelling the growth of the market. Innovations in adjuvants, such as toll-like receptor agonists (TLRs), emulsions, and saponin-based compounds, and rising demand for veterinary vaccines are further likely to boost the adoption and, subsequently, growth of the market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]
Browse in-depth TOC on "Vaccine Adjuvants Market"
200 - Tables
45 - Figures
230 - Pages
The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market
Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. In 2022, the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. Increased use of adjuvant emulsions in the vaccine production is serving as driving factor for the growth of the adjuvant emulsions segment during the forecast period.
The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market
The infectious diseases segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising demand for novel adjuvanted vaccines for infectious diseases. Rising focus on development of plant-based adjuvants is further likely to have positive impact on the segmental growth.
The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of adjuvanted vaccine among the patent population.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Key Market Players:
The vaccine adjuvants market is competitive, with a small number of players competing for market shares. Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), SEPPIC (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
GSK Plc is one of the prominent players in vaccine adjuvants market. The company boasts strong research and development capabilities, a comprehensive adjuvant portfolio, and a strategic focus on innovative formulations. As a global leader in the vaccine adjuvants market, GSK leverages its extensive presence across North America, Europe, Asia, and emerging markets. This broad geographical reach enables GSK to address diverse healthcare needs and capitalize on regional growth opportunities in vaccine development and delivery.
SEPPIC, a leading player in the vaccine adjuvants market, is renowned for its innovative and versatile adjuvant solutions. Its key strengths include a diverse product portfolio featuring squalene-based emulsions, polymer-based adjuvants, and other advanced formulations tailored for both human and veterinary vaccines. The company has a robust geographic presence, with strong operations in Europe, North America, and emerging markets, allowing it to support global vaccine development initiatives. The company prioritizes R&D investments to develop next-generation adjuvants that improve immunogenicity and address unmet needs in human and veterinary vaccines. Its focus on the launch of new products further strengthens the market position. In October 2022, the company launched MONTANIDE GR 01, which is used to formulate veterinary oral vaccines by emulsification with aqueous antigens.
Croda International Plc. is a global leader in vaccine adjuvants, leveraging its extensive geographic presence and strong R&D capabilities. With operations spanning North America, Europe, and emerging markets in Asia Pacific and Latin America. The company offers a diverse portfolio of high-quality adjuvants, including novel technologies tailored to enhance vaccine efficacy and stability. Its advanced manufacturing facilities adhere to stringent regulatory standards, ensuring consistent supply. Croda's strategic choices in the vaccine adjuvants market reflect its commitment to innovation, sustainability, and global expansion.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vaccine-adjuvants-market-worth-096-billion-by-2029]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vaccine Adjuvants Market worth $0.96 billion by 2029 here
News-ID: 3865827 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for GSK
GSK plc (NYSE: GSK) Investor Alert: Deadline in Lawsuit on April 7, 2025
A deadline is coming up on April 7, 2025 in the lawsuit filed for certain investors of GSK plc (NYSE: GSK) over alleged securities laws violations by GSK plc.
Investors who purchased shares of GSK plc (NYSE: GSK) have certain options and there are strict and short deadlines running. Deadline: April 7, 2025. GSK plc (NYSE: GSK) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According…
Lawsuit filed for Investors in shares of GSK plc (NYSE: GSK) over alleged Securi …
An investor, who purchased shares of GSK plc (NYSE: GSK), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by GSK plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of GSK plc (NYSE: GSK) have certain options and for certain investors are short and strict deadlines running. Deadline: April 7, 2025. NYSE: GSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Zoster Vaccine Live Market | GSK, Merck, ,
The global zoster vaccine live market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the zoster vaccine live market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Investigation announced for Investors in GSK plc (NYSE: GSK) over potential Wron …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at GSK plc.
Investors who purchased shares of GSK plc (NYSE: GSK) and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain GSK directors breached their fiduciary duties and caused damage to the company and its shareholders.
United Kingdom based GSK plc, together with its…
Investigation announced for Investors in shares of GSK plc (NYSE: GSK) over poss …
An investigation was announced for investors of GSK plc (NYSE: GSK) shares over potential securities laws violations by GSK plc.
Investors who purchased shares of GSK plc (NYSE: GSK), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by GSK plc regarding its business, its prospects and its operations were materially…
Vaccines Industry Market Growth Prospects And Outlook 2022-2027| GSK, Sanofi, Me …
The Vaccines market outlook looks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain, future roadmaps and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report.
Top Companies in the Global…
